AIM earnings analysis
What we found in AIM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial trends, so current-quarter revenue, margins, EPS, liquidity, and free cash flow cannot be assessed from the available filing content. The principal disclosed update is substantial equity financing: approximately $10.4 million of gross proceeds during the six months ended June 30, 2026, alongside approximately 48.5 million warrants outstanding. Management specifically warns that warrant exercise or future capital raises may cause significant dilution, supporting a bearish risk assessment.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Raised $10.4M Through Equity Transactions
- The company completed multiple equity transactions during the six months ended June 30, 2026, raising approximately $10.4 million in aggregate gross proceeds. The transactions included a rights offering, inducement transactions, and registered direct offerings.
- 48.5M Warrants Outstanding
- The filing identifies approximately 48.5 million warrants outstanding as of June 30, 2026, providing potential future capital if exercised, although the filing emphasizes associated dilution risk.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Shareholder Dilution
- During the six months ended June 30, 2026, equity transactions raised approximately $10.4 million but resulted in issuance of a substantial number of common shares, preferred shares, and warrants. Approximately 48.5 million warrants were outstanding as of June 30, 2026; full exercise could significantly dilute existing stockholders and sales of the underlying shares could depress the stock price.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the extracted 10-Q text; the filing does not state that prior guidance was raised, maintained, lowered, or withdrawn.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- AIM ImmunoTech's Q1 2026 results revealed total revenue of $16 million, significantly below the consensus estimate of $134.3 million, while reporting an EPS of -0.05, slightly better than the expected -0.17. The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AIM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever